Kamada : New Orphan Drug Designation by the FDA, for its Aerosolized AAT for the treatment of Bronchiectasis

April 8th, 2008 - Kamada, a biopharmaceutical company which develops, manufactures and markets specialty life-saving therapeutics, announces today that the company was granted an Orphan Drug Designation to its Aerosolized Alpha-1 Antitrypsin (AAT) product to treat Bronchiectasis.
Kamada's aerosolized AAT product for treating Bronchiectasis, a lung disease that results in the distortion of one or more of the conducting bronchi or airways, is currently undergoing Phase II clinical trials... Kamada's Press Release -

Kamada : Phase III Clinical Trial with Intravenous AAT

April 02, 2008 - Kamada, a biopharmaceutical company developing, producing and marketing a line of specialty, life-saving therapeutics, announced that it has successfully met the primary endpoint in the Phase III US clinical trials with its intravenous Alpha-1 Antitrypsin (AAT). The product is used to treat hereditary AAT deficiency which leads to Congenital Emphysema... Kamada's Press Release -

Kamada : Advancement in its Phase II Trial with Aerosolized AAT to treat CF: First Group of Patients Completes Treatment

March 19, 2008 - Kamada, a biopharmaceutical company developing, manufacturing and marketing specialty, life-saving therapeutics, announces of an advancement in the company's Phase II clinical trial to test the efficacy of its aerosolized AAT (Alpha-1 Antitrypsin) product delivered via an optimized eFlow electronic nebulizer (PARI Pharma) to treat Cystic Fibrosis (CF). The first group of patients has completed treatment with a satisfactory safety profile and with no special adverse events. The trial is ongoing, according to original planned timelines, with the company's aim to complete it by the end of 2008... Kamada 's Press Release -

Kamada, Phase I Studies with Aerosolized AAT for the Treatment of Lung Diseases

January 15, 2008 - Kamada (TASE: KMDA), a biopharmaceutical company developing, producing and marketing specialty life-saving therapeutics, has successfully concluded Phase I clinical studies designed to test the safety and tolerability of the aerosolized version of its flagship product, Alpha-1 Antitrypsin (AAT) using an optimized eFlow Electronic Nebulizer (PARI Pharma GmbH) to treat various lung diseases... Kamada's Press Release - PARI 's Press Release-